Maravai Lifesciences Holdings (MRVI) Change in Accured Expenses (2020 - 2026)

Maravai Lifesciences Holdings' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$5.3 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 390.32% year-over-year to -$5.3 million in Q1 2026; TTM through Mar 2026 was -$11.8 million, a 632.97% decrease from a year earlier, with the FY2025 full-year figure at -$4.6 million, up 80.51% from the prior year.
• Change in Accured Expenses rose to -$5.3 million in Q1 2026 per MRVI's latest filing, from -$13.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $24.2 million in Q1 2023 and bottomed at -$24.1 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $1.5 million (2025), against an average of -$578882.4.
• Across the five-year window, Change in Accured Expenses jumped 882.5% in 2022 and plunged 870.77% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at -$5.6 million in 2022, then jumped by 213.99% to $6.4 million in 2023, then plunged by 124.45% to -$1.6 million in 2024, then tumbled by 764.07% to -$13.5 million in 2025, then surged by 60.52% to -$5.3 million in 2026.
• Per Business Quant, the three latest MRVI Change in Accured Expenses figures stand at -$5.3 million (Q1 2026), -$13.5 million (Q4 2025), and $1.5 million (Q3 2025).